Advertisement

American Journal of Clinical Dermatology

, Volume 5, Issue 3, pp 145–152 | Cite as

Assessing Treatment Outcomes in Toenail Onychomycosis Clinical Trials

  • W. Philip Werschler
  • George Bondar
  • David Armstrong
Current Opinion

Abstract

Several oral and topical medications are available for the treatment of onychomycosis, a widespread fungal infection of the nail. Since efficacy criteria vary greatly among clinical trials for onychomycosis treatment, it is difficult for physicians to compare outcomes and determine the appropriate therapy for a given patient. The present analysis evaluates the efficacy criteria used in intention-to-treat clinical trials of itraconazole, terbinafine, and 8% ciclopirox nail lacquer, drugs approved by the US FDA for the treatment of onychomycosis.

Efficacy parameters often appear to use subjective assessment tools and may not include the actual size measurement of the affected target nail as an efficacy variable. Parameters, which assess both mycologic and clinical cure, are frequently omitted from clinical trials. Not surprisingly, clinical trials with stringent efficacy criteria, which assess both mycologic and clinical response/cure without use of subjective methods, appear to have the lowest rates for both therapeutic response and complete cure. Thus, an evaluation of treatment options for onychomycosis cannot solely compare success/failure rates in clinical trials, but requires a critical appraisal of the efficacy criteria utilized in those trials.

Keywords

Itraconazole Terbinafine Clinical Cure Efficacy Parameter Nail Plate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

This review was supported by Dermik Laboratories.

References

  1. 1.
    Andre J, Achten G. Onychomycosis. Int J Dermatol 1987; 26: 481–90PubMedCrossRefGoogle Scholar
  2. 2.
    Baran R, Hay RJ, Tosti A, et al. A new classification of onychomycosis. Br J Dermatol 1998; 139: 567–71PubMedCrossRefGoogle Scholar
  3. 3.
    Haneke E, Roseeuw D. The scope of onychomycosis: epidemiology and clinical features. Int J Dermatol 1999; 38 Suppl. 2: 7–12PubMedCrossRefGoogle Scholar
  4. 4.
    Werschler WP, Smith SA, Bondar GL. Treatment of onychomycosis in the elderly. Clin Geriatr 2002; 10: 19–24, 29–30Google Scholar
  5. 5.
    Levy LA. Epidemiology of onychomycosis in special-risk populations. J Am Podiatr Med Assoc 1997; 87: 546–50PubMedGoogle Scholar
  6. 6.
    Tom CM, Kane MP. Management of toenail onychomycosis. Am J Health Syst Pharm 1999; 56: 865–71PubMedGoogle Scholar
  7. 7.
    Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000; 43 (4 Suppl.): S57–69CrossRefGoogle Scholar
  8. 8.
    Del Rosso JQ. Advances in the treatment of superficial fungal infections: focus on onychomycosis and dry tinea pedis. J Am Osteopath Assoc 1997; 97: 339–46PubMedGoogle Scholar
  9. 9.
    Hay RJ. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol 2001; 145: 3–8PubMedGoogle Scholar
  10. 10.
    Elewski BE, Hay RJ. Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin Infect Dis 1996; 23: 305–13PubMedCrossRefGoogle Scholar
  11. 11.
    Trepanier EF, Amsden GW. Current issues in onychomycosis. Ann Pharmacother 1998; 32: 204–14PubMedCrossRefGoogle Scholar
  12. 12.
    Weinberg JM, Koestenblatt EK. Comparison of diagnostic methods in the evaluation of onychomycosis. Dermatol Online J 2001; 7: 236Google Scholar
  13. 13.
    Midgley G, Moore MK, Cook JC, et al. Mycology of nail disorders. J Am Acad Dermatol 1994; 31 (3 Pt 2): S68–74CrossRefGoogle Scholar
  14. 14.
    Daniel CR, Elewski BE. The diagnosis of nail fungus infection revisited. Arch Dermatol 2000; 136: 1162–4PubMedCrossRefGoogle Scholar
  15. 15.
    Sorrentino A, Haber G, Solotoff S. Update on treatments for onychomycosis. Drug Topics 2000 Sep; Suppl.: 3–12Google Scholar
  16. 16.
    Lawry MA, Haneke E, Strobeck K, et al. Methods for diagnosing onychomycosis: a comparative study and review of the literature. Arch Dermatol 2000; 136: 1112–6PubMedCrossRefGoogle Scholar
  17. 17.
    Elewski BE, Scher RK, Aly R, et al. Double-blind, randomized comparison of itraconazole capsules vs placebo in the treatment of toenail onychomycosis. Cutis 1997; 59: 217–20PubMedGoogle Scholar
  18. 18.
    Haneke E, Abeck D, Ring J. Safety and efficacy of intermittent therapy with itraconazole in finger- and toenail onychomycosis: a multicentre trial. Mycoses 1998; 41: 521–7PubMedCrossRefGoogle Scholar
  19. 19.
    Pollak R, Billstein SA. Efficacy of terbinafine for toenail onychomycosis: a multicenter trial of various treatment durations. J Am Podiatr Med Assoc 2001; 91: 127–31PubMedGoogle Scholar
  20. 20.
    Gupta AK, Lynde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol 2001; 44: 485–91PubMedCrossRefGoogle Scholar
  21. 21.
    Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000; 43 (4 Suppl.): S70–80CrossRefGoogle Scholar
  22. 22.
    Fleckman P. Basic science of the nail unit. In: Scher RK, Daniel III CR, editors. Nails: therapy, diagnosis, surgery. Philadelphia (PA): WB Saunders, 1990: 36–51Google Scholar
  23. 23.
    De Cuyper C, Hindryckx PH. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol 1999; 141: 15–20PubMedCrossRefGoogle Scholar
  24. 24.
    Sporanox® [package insert]. Titusville (NJ): Janssen Pharmaceutica Products, L.P., 2001Google Scholar
  25. 25.
    Lamisil® [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2001Google Scholar
  26. 26.
    Penlac™ nail lacquer [package insert]. Berwyn (PA): Dermik Laboratories, 2000Google Scholar
  27. 27.
    Roberts DT. Onychomycosis: current treatment and future challenges. Br J Dermatol 1999; 141 Suppl. 56: 1–4PubMedCrossRefGoogle Scholar
  28. 28.
    De Doncker PR, Scher RK, Baran RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997; 36: 173–7PubMedCrossRefGoogle Scholar
  29. 29.
    Havu V, Brandt H, Heikkila H, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis. Br J Dermatol 1997; 136: 230–4PubMedCrossRefGoogle Scholar
  30. 30.
    Gupta AK, De Doncker P, Scher RK, et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol 1998; 37: 303–8PubMedCrossRefGoogle Scholar
  31. 31.
    Alpsoy E, Yilmaz E, Basaran E. Intermittent therapy with terbinafine for dermatophyte toe-onychomycosis: a new approach. J Dermatol 1996; 23: 259–62PubMedGoogle Scholar
  32. 32.
    Tosti A, Piraccini BM, Stinchi C, et al. Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595–600PubMedCrossRefGoogle Scholar
  33. 33.
    Gupta AK. Management options in onychomycosis. Am J Med Sports 2000; 2: 117–8, 128Google Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • W. Philip Werschler
    • 1
  • George Bondar
    • 2
  • David Armstrong
    • 3
  1. 1.Medicine and DermatologyUniversity of Washington School of MedicineSeattleUSA
  2. 2.MOHS SurgerySpokane Dermatology ClinicSpokane ValleyUSA
  3. 3.Dr William Scholl College of Podiatric MedicineRosalind Franklin University of Medicine and ScienceChicagoUSA

Personalised recommendations